Merieux Developpement is the famous VC, which was founded in 2009. The main office of represented VC is situated in the Lyon. The company was established in Europe in France.
The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2018. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Merieux Developpement works on 2 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 deals per year.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Merieux Developpement, startups are often financed by Paladin Capital Group, Foresite Capital, NanoDimension. The meaningful sponsors for the fund in investment in the same round are NanoDimension, Shire, Paladin Capital Group. In the next rounds fund is usually obtained by Shire, Venrock, Paladin Capital Group.
The current fund was established by Francois Valencony. The overall number of key employees were 9.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Pharmaceutical, Manufacturing. Among the most popular portfolio startups of the fund, we may highlight Origene Technologies, Amphivena Therapeutics, Inscripta, Inc.
Related Funds
Funds with similar focus
Fund Name | Location |
Angel Investment Fang Yonghua Investment | - |
Asia Plus | Chicago, Illinois, United States |
Aviva Ventures | England, London, United Kingdom |
Bank Muscat | Masqat, Muscat, Oman |
Bowman Capital | California, San Mateo, United States |
China Life APM Asset Management | Beijing, Beijing, China |
China Unicom | Beijing, Beijing, China |
Go-Ventures | Indonesia, Jakarta, Jakarta Raya |
Grey Sky Venture Partners | Bellevue, United States, Washington |
Huntington National Bank | Columbus, Ohio, United States |
IK Investment Partners | England, London, United Kingdom |
InnoCal Venture Capital | California, Costa Mesa, United States |
Loxbridge Research | England, London, United Kingdom |
NGC Ventures | Central Region, Singapore, Singapore |
Pablo Capital | - |
Pilot Wall Group | Austin, Texas, United States |
Shenzhen Qianhai Zhongyinhui Investment Management | China, Guangdong, Shenzhen |
Technicolor | California, United States, West Hollywood |
Up North | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
keepMED | $15M | 29 Sep 2020 | North District | ||
Amphivena Therapeutics | $62M | 24 Sep 2019 | South San Francisco, California, United States | ||
Inscripta | $20M | 04 Apr 2019 | Boulder, Colorado, United States | ||
Inscripta | $30M | 19 Dec 2018 | Boulder, Colorado, United States | ||
Xeris Pharmaceuticals | $10M | 08 Mar 2018 | Chicago, Illinois, United States | ||
Inscripta | $55M | 28 Feb 2018 | Boulder, Colorado, United States | ||
PhysioAssist | $7M | 18 Sep 2017 | Provence-Alpes-Côte d'Azur | ||
Xeris Pharmaceuticals | $30M | 19 May 2017 | Chicago, Illinois, United States | ||
$25M | 09 Jan 2017 | Irvine, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
keepMED | $15M | 29 Sep 2020 | North District | ||
Amphivena Therapeutics | $62M | 24 Sep 2019 | South San Francisco, California, United States | ||
Inscripta | $20M | 04 Apr 2019 | Boulder, Colorado, United States | ||
Inscripta | $30M | 19 Dec 2018 | Boulder, Colorado, United States | ||
Xeris Pharmaceuticals | $10M | 08 Mar 2018 | Chicago, Illinois, United States | ||
Inscripta | $55M | 28 Feb 2018 | Boulder, Colorado, United States | ||
PhysioAssist | $7M | 18 Sep 2017 | Provence-Alpes-Côte d'Azur | ||
Xeris Pharmaceuticals | $30M | 19 May 2017 | Chicago, Illinois, United States | ||
$25M | 09 Jan 2017 | Irvine, California, United States |